Endocrinology Part 1

📚 02 Pediatric Superspecialities • 🎯 117 High-Yield MCQs • Nelson 22nd Edition Standard

Turner and Klinefelter Syndromes

  • Klinefelter Variants (>=3 X Chromosomes): ((ENDO1001)): Variants like 49,XXXXY manifest with severe intellectual disability and distinct dysmorphic features since early childhood; severity of cognitive impairment and virilization failure scales directly with the number of X chromosomes exceeding two. Conversely, 48,XXYY adults are typically taller but lack this profound cognitive decrement.
  • Turner Syndrome Cardiac Manifestations: ((ENDO1003)): The most common cardiac defect is an isolated nonstenotic bicuspid aortic valve (present in 1/3 to 1/2 of patients), which risks progressive aortic root dilatation. Coarctation of the aorta occurs in approximately 20% (strongly associated with webbed necks).

Hypogonadotropic Hypogonadism & DSD

  • Kallmann Syndrome Genetics: ((ENDO1002)): Autosomal dominant Kallmann syndrome (KAL2) arises from loss-of-function mutations in the FGFR1 gene and frequently features cleft lip and cleft palate. In contrast, X-linked Kallmann is caused by mutations in the KAL1 gene (product: anosmin-1).
  • WT1-Related Disorders (Frasier Syndrome): ((ENDO1009)): Caused by intron 9 mutations in the WT1 gene, manifesting as 46,XY gonadal dysgenesis + late-onset focal segmental glomerulosclerosis (FSGS) + gonadoblastoma without Wilms tumor. (Distinction: Denys-Drash syndrome presents early with nephropathy, ambiguous genitalia, and bilateral Wilms tumor).

Congenital Adrenal Hyperplasia (CAH) & Mineralocorticoid Disorders

  • CAH Genital Presentations: ((((ENDO1011)) · ((ENDO1012)))): - 11β-Hydroxylase and 21-hydroxylase deficiencies preserve the adrenal androgen pathway, yielding normal male genitalia at birth while virilizing female newborns. - 17α-Hydroxylase deficiency disrupts androgen synthesis, producing undervirilized/ambiguous male newborns and normal-looking female genitalia (with subsequent sexual infantilism).
  • Hypertensive CAH Variants: ((ENDO1013)): 11β-Hydroxylase deficiency causes hypertension due to the accumulation of deoxycorticosterone (DOC) with mineralocorticoid activity, leading to suppressed renin and low aldosterone levels.
  • Apparent Mineralocorticoid Excess (AME): ((ENDO1017)): Caused by inactivating mutations in the HSD11B2 gene (deficiency of the enzyme converting cortisol to cortisone). This permits cortisol to bind renal mineralocorticoid receptors, phenocopying hyperaldosteronism. (Distinction: Liddle syndrome involves constitutive activation of the ENaC gene).

Diabetes Mellitus & Endocrine Pancreas

  • MODY 5 (HNF1β Mutations): ((ENDO1004)): Characterized by antibody-negative, insulin-dependent diabetes mellitus associated with renal malformations, uterine abnormalities, and pancreatic exocrine insufficiency; does not respond to sulfonylureas.
  • Type 1 Diabetes Staging: ((ENDO1005)): Stage 2 T1D is defined by the presence of two or more diabetes-related autoantibodies with dysglycemia but absence of symptoms. (Stage 1 = autoantibodies with normal blood sugar; Stage 3 = clinical diagnosis).
  • Oral Glucose Tolerance Test (OGTT) Cutoffs: ((ENDO1006)): Impaired glucose tolerance (IGT) is defined by a 2-hour plasma glucose of 140–199 mg/dL. (Diabetes mellitus is diagnosed at $\ge$200 mg/dL).
  • Diabetic Nephropathy Management: ((ENDO1026)): Persistent microalbuminuria (urinary albumin excretion 30–300 mg/24 hours) in Type 1 Diabetes warrants initiation of ACE inhibitors to reduce efferent arteriolar transglomerular pressure, alongside rigorous blood pressure and lipid control.

Growth and Anterior Pituitary Axis

  • Laron Syndrome Treatment: ((ENDO1008)): Caused by GH insensitivity; treated directly with recombinant IGF-1 (Mecasermin) since upstream GH therapy is ineffective. Mecasermin is also indicated for STAT5b mutations.
  • Cranial Irradiation Sequelae: ((ENDO1031)): Growth hormone deficiency (GHD) is almost universal 5 years after a radiation dose of $\ge$35 Gy.
  • rhGH Adverse Effects: ((((ENDO1032)) · ((ENDO1033)))): Recombinant GH therapy risks Slipped Capital Femoral Epiphysis (SCFE) (manifesting as hip pain/limping) and pseudotumor cerebri. Creutzfeldt-Jakob disease was historically linked strictly to pituitary-derived human GH extracts, not recombinant preparations.
  • Tall Stature Management Thresholds: ((ENDO1035)): Estrogen/androgen height-reducing therapies must be initiated early—before bone age reaches 12 years in girls and 14 years in boys.

Thyroid Disorders

  • Thyroid Dysgenesis Genetics: ((ENDO1024)): Athyreosis accompanied by cleft palate, choanal atresia, kinky hair, and bifid epiglottis is caused by mutations in the FOXE1 gene.
  • Pendred Syndrome: ((ENDO1025)): Characterized by sensorineural deafness and goiter due to pathogenic variants in the SLC26A4 gene encoding the chloride-iodide transporter pendrin.
  • Hypothyroidism-Induced Sexual Precocity: ((ENDO1020)): Profound primary hypothyroidism drives precocious puberty via massively elevated TSH levels, which cross-react with ovarian FSH receptors due to structural alpha-subunit homology, generating estrogen-secreting ovarian cysts.

Calcium and Parathyroid Disorders

  • Familial Hypocalciuric Hypercalcemia (FHH): ((ENDO1019)): A form of PTH-dependent hypercalcemia caused by an inactivating mutation in the Ca2+-sensing receptor (CaSR) gene, leading to increased renal tubular calcium reabsorption and relative hypocalciuria.

Adrenal Insufficiency & Syndromes

  • Secondary vs Primary Adrenal Insufficiency: ((ENDO1015)): Secondary and tertiary adrenal insufficiency do not feature hyperpigmentation because pituitary ACTH (and associated POMC-derived $\alpha$/$\beta$-MSH peptides) levels are low/normal, unlike primary adrenal insufficiency (Addison disease) where ACTH is elevated.
  • Allgrove (AAA) Syndrome: ((ENDO1016)): Characterized by the triad of alacrimia, achalasia, and adrenal insufficiency, caused by mutations in the AAAS gene (affecting the nuclear pore protein ALADIN).
  • Adrenal Crisis in Nephrotic Syndrome: ((ENDO1027)): Children with frequently relapsing nephrotic syndrome on chronic steroids presenting in shock during mild intercurrent illness are experiencing glucocorticoid-induced secondary adrenal crisis and require immediate IV hydrocortisone stress dosing.

Pubertal Disorders & Neoplasia

  • McCune-Albright Syndrome (MAS): ((ENDO1030)): Caused by post-zygotic activating mutations in the GNAS gene (constitutive cAMP signaling). Presents with the classic triad of peripheral precocious puberty (episodic autonomous ovarian cysts with suppressed gonadotropins), polyostotic fibrous dysplasia (lytic lesions with ground-glass appearance), and café-au-lait macules with irregular "Coast of Maine" borders.
  • Pheochromocytoma Syndromes: ((ENDO1014)): Associated with VHL, MEN2, and NF1, but not MEN1 (which features parathyroid, pituitary, and pancreatic neuroendocrine tumors).

Precocious Puberty & Disorders of Puberty

  • Central Precocious Puberty (CPP) Therapy: ((((ENDO1036)) · ((ENDO1037)) · ((ENDO1038)) · ((ENDO1061)))): GnRH agonist therapy (e.g., depot leuprolide) is the treatment of choice for CPP to halt pubertal progression, preserve adult height, and prevent psychosocial distress. - Least benefit: 7-year-old girls with slowly progressive idiopathic CPP and minimal bone age advancement ((ENDO1036)). - Hypothalamic hamartomas are the most common brain lesions causing CPP; treatment remains GnRH agonists (not surgery/gamma knife) ((ENDO1061)).
  • Initial Flare Phenomenon: : During the first 1-2 weeks, continuous GnRH agonist exposure initially stimulates pituitary gonadotrophs, transiently increasing LH, FSH, and sex steroids, causing mild temporary progression of secondary sexual characteristics ((ENDO1037)).
  • Treatment Efficacy: : The single most important therapeutic outcome is slowing of osseous (bone) maturation ((ENDO1038)).
  • Peripheral vs. Central Precocious Puberty & Virilization: ((((ENDO1050)) · ((ENDO1051)) · ((ENDO1052)) · ((ENDO1053)))):
  • Peripheral Precocious Puberty: : Characterized by prepubertal testicular volume (<4 mL) in boys, indicating gonadotropin-independent sex steroid production. Associated with Congenital Adrenal Hyperplasia (CAH) (elevated 17-OH progesterone, salt-wasting) ((ENDO1050)) or hepatoblastoma (secreting hCG, mimicking LH, causing isolated penile enlargement and voice change with normal testes) ((ENDO1051)).
  • Androgen Insensitivity Syndromes: : - Complete AIS: 46,XY with female external genitalia, normal breasts, absent axillary/pubic hair, primary amenorrhea, palpable inguinal gonads (testes), and absent Müllerian structures due to AMH action ((ENDO1052)). - Mayer-Rokitansky-Küster-Hauser (MRKH) Syndrome: Normal female phenotype with normal breasts and hair, primary amenorrhea, blind vaginal pouch, and absent uterus/upper vagina with normal ovaries ((ENDO1053)). ---

Thyroid Disorders & Congenital Hypothyroidism

  • Inborn Errors of Thyroid Hormone Synthesis & Transport: ((((ENDO1039)) · ((ENDO1040)))):
  • Defective Iodotyrosine Deiodinase (IYD/DEHAL1 gene): : Causes severe iodine loss via urinary excretion of monoiodotyrosine and diiodotyrosine, leading to early hypothyroidism and goiter despite adequate dietary iodine ((ENDO1039)).
  • Thyroid Scintigraphy Mimics: : Absent radioactive iodine uptake mimicking thyroid agenesis can occur due to TSH receptor defects, maternal TSH receptor-blocking antibodies, and sodium-iodide symporter defects. Conversely, thyroid hormone synthesis defects present with a normally located gland and normal or increased radionuclide uptake ((ENDO1040)).
  • Thyroid Syndromes & Non-Autoimmune Hypothyroidism: ((((ENDO1041)) · ((ENDO1047)) · ((ENDO1048)))):
  • Williams Syndrome: : Associated with persistent subclinical hypothyroidism characterized by repeatedly negative thyroid autoantibodies (differentiating it from Turner syndrome or trisomy 21) ((ENDO1041)).
  • Consumptive Hypothyroidism: : Occurs in infants with large hepatic vascular hemangiomas/hamartomas overexpressing type 3 deiodinase, inactivating T4 and T3 to reverse T3 and T2, causing refractory hypothyroidism despite escalating levothyroxine doses ((ENDO1048)).
  • Thionamides: : Methimazole is preferred over propylthiouracil (PTU) due to lower risk of severe hepatotoxicity/liver failure ((ENDO1047)). ---

Adrenal Disorders & Cushing Syndrome

  • Congenital Adrenal Hyperplasia & Adrenal Tumors: ((((ENDO1042)) · ((ENDO1043)))):
  • X-Linked Adrenoleukodystrophy (ALD): : Peroxisomal disorder caused by mutations in ABCD1, presenting with primary adrenal insufficiency (Addisonian crisis, hyperpigmentation) and neurological decline. Diagnosis is confirmed by elevated very long-chain fatty acids (VLCFA), specifically hexacosanoic acid (C26:0) ((ENDO1042)).
  • Adrenocortical Carcinoma: : Presents with signs of endocrine hyperfunction (sex steroid excess, Cushingoid features) and a unilateral suprarenal mass ((ENDO1043)).
  • Cushing Syndrome Diagnostic Workup: ((ENDO1044)):
  • Low-dose dexamethasone suppression test: : Sensitive screening test to confirm endogenous Cushing syndrome of any etiology.
  • High-dose dexamethasone suppression test: : Differentiates pituitary Cushing disease from ectopic ACTH or adrenal tumors, as only pituitary disease shows suppression to high doses ((ENDO1044)). ---

Calcium, Parathyroid, & Bone Metabolism

  • Hypocalcemia & Pseudohypoparathyroidism: ((((ENDO1045)) · ((ENDO1046)))):
  • Pseudohypoparathyroidism Type 1a (PHP 1a): : Characterized by hypocalcemia, hyperphosphatemia, high PTH, and Albright Hereditary Osteodystrophy (AHO) phenotype. Caused by an inactivating loss-of-function mutation in the Gsα subunit gene (GNAS), leading to decreased urinary cAMP response to PTH ((ENDO1045)). (Contrast with McCune-Albright syndrome, which involves a gain-of-function mutation in Gsα) ((ENDO1045)).
  • DiGeorge Syndrome (CATCH 22): : 22q11.2 deletion manifesting with conotruncal cardiac defects, abnormal facies, thymic aplasia, cleft palate, and neonatal hypocalcemia due to hypoparathyroidism from 3rd/4th pharyngeal pouch maldevelopment ((ENDO1046)). ---

Diabetes Mellitus & Metabolic Management

  • Type 1 Diabetes: Acute Complications & Management: ((((ENDO1049)) · ((DST1054)) · ((ENDO1055)) · ((ENDO1056)) · ((ENDO1057)))):
  • Morning Hyperglycemia (Dawn vs. Somogyi): : Differentiated by checking 3 AM blood glucose levels. Dawn phenomenon (growth hormone/cortisol surge) shows high 3 AM and morning sugars; Somogyi phenomenon (rebound from nocturnal hypoglycemia) shows low 3 AM blood sugar ((ENDO1049)).
  • Sick-Day Rules: : Never omit basal insulin. Insulin requirements usually increase during illness due to counterregulatory hormones; monitor blood glucose and ketones frequently and adjust rapid-acting insulin ((ENDO1054)).
  • Hypoglycemia Protocol: : Treat mild-to-moderate hypoglycemia immediately regardless of symptoms using the 15-15 rule (15 g of fast-acting carbohydrate / 3 tsp table sugar in water, recheck in 15 minutes) ((ENDO1055)).
  • Diabetic Ketoacidosis (DKA) Initial Resuscitation: : The mandatory first intervention in the casualty is an isotonic normal saline fluid bolus to restore intravascular volume, improve renal perfusion, and reduce counterregulatory hormones, prior to initiating an insulin infusion ((ENDO1056)).
  • Cystic Fibrosis-Related Diabetes (CFRD): : Characterized by primary insulin deficiency; the required treatment is insulin (not oral hypoglycemics or lifestyle modifications) ((ENDO1057)). ---

Hypothalamic-Pituitary Axis & Growth Disorders

  • Congenital Hypopituitarism & Genetic Syndromes: ((((ENDO1060)) · ((ENDO1062)) · ((ENDO1063)))):
  • Congenital Isolated Hypogonadotropic Hypogonadism (CHH): : Presents in infant boys with micropenis and normal testes during minipuberty (first 3-6 months), characterized by low LH, FSH, and testosterone ((ENDO1060)).
  • Hall-Pallister Syndrome: : Caused by loss-of-function mutations in GLI3, featuring absent pituitary, hypothalamic hamartoma, postaxial polydactyly, nail dysplasia, bifid epiglottis, and imperforate anus ((ENDO1062)).
  • Recessive Multiple Pituitary Hormone Deficiency: : Most frequently caused by pathogenic variants in PROP1 (presenting with growth hormone deficiency first, followed later by TSH, gonadotropins, and ACTH deficiencies) ((ENDO1063)).
  • Growth Hormone Deficiency (GHD) & Short Stature: ((((ENDO1064)) · ((ENDO1065)) · ((ENDO1066)) · ((ENDO1067)))):
  • Diagnostic Confirmation: : Provocative GH testing can be omitted if auxologic findings of GHD are present alongside a structural hypothalamic-pituitary abnormality and an additional pituitary hormone deficiency (e.g., central hypothyroidism) ((ENDO1064)).
  • Thyroid Replacement Rule: : Provocative GH test results are uninterpretable in untreated hypothyroidism; thyroid hormone deficiency must be corrected first, as low thyroid levels suppress GH synthesis ((ENDO1065)).
  • Idiopathic Short Stature (ISS): : Height >2.25 SD below mean, normal GH provocation, and normal/low-normal IGF-1. Responds to GH therapy, but the final adult height benefit is unpredictable ((ENDO1066)).
  • Monitoring GH Therapy: : If growth velocity drops below the 25th percentile during rhGH therapy, the mandatory first step is to measure serum IGF-1 to assess treatment adherence before modifying the dose ((ENDO1067)).
  • Diabetes Insipidus (DI): ((((ENDO1068)) · ((ENDO1069)) · ((ENDO1070)))):
  • Diagnostic Evaluation: : Polyuria/polydipsia with serum osmolality >300 mOsm/kg and urine osmolality <300 mOsm/kg confirms DI. A baseline copeptin >20 pmol/L confirms nephrogenic DI, bypassing the need for a water deprivation test ((ENDO1068)).
  • Syndromic Associations: : Unlike optic nerve hypoplasia, holoprosencephaly, and Niikawa-Kuroki syndrome, Wolfram syndrome (WFS1/WFS2) is a neurodegenerative disorder (diabetes insipidus, diabetes mellitus, optic atrophy, deafness) not classified among congenital brain malformations causing DI ((ENDO1069)).
  • Acute Post-Operative Central DI: : Best managed with continuous intravenous aqueous vasopressin infusion titrated to urine output and serum sodium, restricting total fluid intake to ~1 L/m²/24 hr ((ENDO1070)).

Water Balance & Diabetes Insipidus

  • Acquired Nephrogenic Diabetes Insipidus (NDI): ((ENDO1071)): Caused by renal resistance to vasopressin. Established metabolic/drug causes include hypercalcemia, hypokalemia, lithium, demeclocycline, foscarnet, clozapine, amphotericin, methicillin, and rifampin. *Quetiapine* is not a cause.
  • Congenital Nephrogenic Diabetes Insipidus (NDI): ((ENDO1072)): Standard therapy requires adequate calories, hydration, solute restriction, and thiazide diuretics (induces mild volume depletion, reducing GFR and increasing proximal tubular reabsorption), often combined with amiloride or indomethacin. Rare exception: Patients with specific V2 receptor mutations showing reduced vasopressin-binding affinity respond to high-dose DDAVP plus indomethacin.

Hyponatremia & Postoperative Electrolyte Disorders

  • Cerebral Salt Wasting (CSW): ((ENDO1073)): Characterized by postoperative hyponatremia, markedly elevated urine sodium, increased urine output, and hypovolemia. While supine blood pressure may be preserved, a significant postural fall in blood pressure confirms reduced effective circulating volume.
  • Exercise-Associated ("Runner's") Hyponatremia: ((ENDO1074)): Occurs after excessive ingestion of hypotonic fluids during prolonged endurance exercise (e.g., marathons) coupled with hypovolemia-induced AVP secretion. Features post-race weight gain greater than pre-race weight, hyponatremia, reduced intravascular volume, and low urine sodium.
  • Correction of Chronic Hyponatremia: ((ENDO1075)): Restoring effective plasma volume withdraws nonosmotic vasopressin stimulation, triggering brisk water diuresis and a rapid rise in serum sodium. Target correction rate must be <0.5 mEq/L/hr to avoid osmotic demyelination syndrome (central pontine myelinolysis).

Pituitary Disorders & Hyperprolactinemia

  • Pegvisomant in Acromegaly: ((ENDO1076)): A growth hormone receptor antagonist competing with endogenous GH to suppress downstream IGF-1 production. Indicated when surgery is not curative and somatostatin analogs fail to normalize IGF-1 (normalizes IGF-1 in up to 90% of patients). Requires monitoring of IGF-1 and hepatic enzymes.
  • Macroprolactinemia & The "Hook Effect": ((ENDO1077)): Large pituitary macroadenomas with only mildly elevated serum prolactin require suspicion of the hook effect, where extremely high prolactin levels saturate immunoassay antibodies, yielding factitiously low results. Must repeat prolactin measurement after serial dilution.
  • Primary Hypothyroidism with Pituitary Hyperplasia: ((ENDO1078)): Profound primary hypothyroidism causes thyrotroph and lactotroph hyperplasia, mimicking a prolactinoma with diffuse pituitary enlargement, moderate hyperprolactinemia (typically <200 ng/mL), low free T4, and markedly elevated TSH. Treated with thyroid hormone replacement alone.

Tall Stature & Overgrowth Syndromes

  • Sotos Syndrome: ((ENDO1079)): Overgrowth disorder caused by NSD1 gene variants/deletions. Features excessive growth in the first 4 years of life, macrocephaly, dolichocephaly, prominent forehead and jaw, hypertelorism, downslanting palpebral fissures, long limbs, hypotonia, developmental delay, and nonfebrile seizures. Growth velocity normalizes after early childhood.
  • Evaluation of Tall Stature: ((ENDO1080)): In a nondysmorphic child with documented recent growth acceleration, the immediate next step is the assessment for pubertal signs (to rule out precocious/pseudoprecocious puberty or constitutional advance) before evaluating for pituitary gigantism or hyperthyroidism.

Precocious Puberty & Variants

  • hCG-Secreting Germinoma: ((ENDO1081)): Causes gonadotropin-independent precocious puberty with pubertal testosterone levels, suppressed basal LH, and prepubertal LH response to GnRH stimulation. Hallmarks include bilateral testicular enlargement due to hCG acting like LH on Leydig cells.
  • Ovarian Granulosa Cell Tumor: ((ENDO1082)): Estrogen-secreting ovarian tumor causing gonadotropin-independent precocious puberty with markedly elevated estradiol, suppressed basal LH, and a palpable adnexal mass on pelvic imaging/examination.
  • Depot Leuprolide Acetate Adverse Effects: ((ENDO1083)): Long-acting GnRH analogs used for central precocious puberty can rarely cause recurrent sterile fluid collections at the injection site (<1–3% of patients).
  • Van Wyk-Grumbach Syndrome: ((ENDO1084)): Rare consequence of long-standing primary hypothyroidism (e.g., Hashimoto thyroiditis) presenting paradoxically with precocious puberty (breast development, vaginal bleeding, multicystic ovaries), markedly elevated TSH, suppressed LH, and delayed bone age despite precocious puberty.
  • Hypothalamic Hamartoma: ((ENDO1085)): Most common brain lesion causing central precocious puberty via TGF-α secretion. MRI shows a static, nonenhancing lesion near the tuber cinereum/third ventricle. Pathognomonic clinical association: Gelastic seizures (brief stereotyped laughter without emotional triggers).
  • Benign Premature Thelarche: ((ENDO1086)): Transient isolated breast development appearing in the first 2 years of life (may be asymmetric or present from birth). Features normal growth velocity and bone age, undetectable basal LH and estradiol, elevated basal FSH response, and normal-sized ovaries or small cysts <9 mm.

Delayed Puberty & Hypogonadism

  • Bardet-Biedl Syndrome: ((ENDO1087)): Genetic disorder featuring hypogonadotropic hypogonadism (delayed puberty), cognitive impairment, obesity, retinitis pigmentosa, and postaxial polydactyly.
  • Isolated Gonadotropin Deficiency: ((ENDO1088)): Delayed puberty with low LH and FSH, normal prior growth pattern, bilaterally small testes (2 mL), and reduced stretched penile length with a normal brain MRI.
  • Primary Amenorrhea with Normal Breast Development: ((ENDO1089)): Requires karyotype analysis as the next step to differentiate an anatomic 46,XX defect (e.g., Müllerian agenesis) from 46,XY androgen insensitivity syndrome (characterized by sparse axillary/pubic hair and ambiguous pelvic imaging regarding a uterus).
  • Fertility in Congenital Hypogonadotropic Hypogonadism: ((ENDO1090)): Testosterone therapy maintains secondary sex characteristics but does not induce spermatogenesis. Cyclical gonadotropin therapy or pump-driven pulsatile GnRH therapy is required when fertility is desired.

Congenital & Acquired Hypothyroidism

  • Congenital TBG Deficiency: ((ENDO1091)): X-linked recessive cause of low total T4 on newborn screening. Features low total T4, elevated T3 resin uptake, normal free T4, and normal TSH in a clinically euthyroid infant. No treatment needed.
  • Thyroperoxidase (TPO) Deficiency: ((ENDO1092)): Causes congenital hypothyroidism with a diffuse goiter and normal radioiodine uptake. Administration of perchlorate results in marked discharge of previously accumulated radioiodine (positive perchlorate discharge test due to impaired iodide organification).
  • Transitory Congenital Hypothyroidism via Maternal Antibodies: ((ENDO1093)): Caused by maternal thyrotropin receptor-blocking antibodies crossing the placenta, leading to a small/normally positioned gland on ultrasound, absent uptake on scintigraphy, and low serum thyroglobulin.
  • Fontanel Sign in Congenital Hypothyroidism: ((ENDO1094)): Clinical manifestations are often absent at birth, but a posterior fontanel wider than 0.5 cm (found in <3% of normal newborns) strongly raises clinical suspicion.
  • Kocher-Debré-Sémélaigne Syndrome: ((ENDO1095)): Rare manifestation of long-standing untreated congenital hypothyroidism featuring generalized muscular pseudohypertrophy, giving an athletic appearance.
  • Levothyroxine Administration in Infancy: ((ENDO1096)): Tablets must be crushed and mixed in 1–2 mL of liquid. Soy protein formulas, concentrated iron, and calcium supplements reduce intestinal absorption and must be avoided/separated.
  • Oxcarbazepine-Induced Hypothyroidism: ((ENDO1097)): Unlike most anticonvulsants (phenytoin, phenobarbital, valproate) that cause subclinical hypothyroidism via increased hepatic clearance, oxcarbazepine uniquely causes central (secondary) hypothyroidism (low free T4 with inappropriately normal/low TSH).
  • Systemic Manifestations of Hypothyroidism: ((ENDO1098)): Includes CKD/reduced eGFR, hyponatremia, muscle weakness, and acquired von Willebrand disease (alongside reduced protein C/S and increased mean platelet volume).

Thyroiditis Syndromes

  • Autoimmune Thyroiditis (Hashimoto): ((((ENDO1099)) · ((ENDO1100)))): Most common cause of acquired hypothyroidism; characteristically painless (unlike subacute granulomatous, radiation, or palpation-induced thyroiditis). Strongly associated with HLA-DR4 and HLA-DR5 (goitrous) and HLA-DR3 (atrophic variant).
  • Autoimmune Polyglandular Syndrome Type 2 (APS-2): ((ENDO1101)): Clustering of autoimmune endocrine/nonendocrine disorders beginning in late childhood/adulthood: autoimmune thyroiditis, type 1 diabetes mellitus, autoimmune primary adrenal insufficiency (Addison disease), pernicious anemia, and vitiligo.
  • Painless Thyroiditis: ((ENDO1102)): Autoimmune transient thyrotoxicosis with a nontender thyroid, normal ESR, persistently positive TPO antibodies, and low radioiodine uptake due to preformed hormone release.

Hyperthyroidism & Graves Disease

  • Graves Disease Manifestations & Complications: ((ENDO1103)): Children present with hyperactivity, accelerated growth, and advanced bone age. Ocular symptoms are typically mild. Cardiac enlargement, insufficiency, and atrial fibrillation are rare in pediatric patients.
  • Methimazole-Induced Agranulocytosis: ((ENDO1104)): Presents with high-grade fever, severe pharyngitis, and oral ulcers. Immediately withhold methimazole and obtain an urgent absolute neutrophil count. Do not wait for results while continuing the drug.
  • Thyroid Storm Management: ((ENDO1105)): Acute decompensation treated with propylthiouracil (inhibits synthesis), potassium iodide (inhibits secretion), prednisone (glucocorticoid), supportive care, and management of triggers. Methimazole is not used in acute storm protocols.

Thyroid Disorders & Malignancies

  • Pediatric Papillary Thyroid Carcinoma: ((ENDO1106)): More commonly driven by somatic gene fusions involving oncogenic tyrosine kinases (*RET*, *NTRK1/3*), unlike adult variants which frequently harbor BRAF or RAS mutations. Medullary thyroid carcinoma arises from parafollicular C cells and links to germline RET variants, while anaplastic and follicular carcinomas follow distinct molecular pathways.
  • Graves' Ophthalmopathy Management: ((ENDO1110)): Characterized clinically by signs such as Dalrymple sign (upper eyelid retraction in primary gaze). Radioactive iodine (RAI) therapy is contraindicated/can worsen ophthalmopathy (especially in smokers) unless high-dose glucocorticoids are co-administered. Management includes antithyroid drugs, glucocorticoids, and orbital radiotherapy.

Adrenal Insufficiency & Polyglandular Syndromes

  • Autoimmune Polyglandular Syndrome Type 1 (APS-1 / APECED): ((ENDO1107)): Presents with primary adrenal insufficiency, chronic mucocutaneous candidiasis, and hypoparathyroidism. Caused by autosomal recessive mutations in the AIRE gene on chromosome 21q22.3. Chronic mucocutaneous candidiasis is typically the earliest manifestation.

Genetic & Overgrowth Syndromes

  • Beckwith-Wiedemann Syndrome (BWS): ((ENDO1111)): An overgrowth malformation syndrome caused by genetic or epigenetic abnormalities in the 11p15 chromosomal region. Features include macrosomia, omphalocele, macroglossia, and ear pits/creases.
  • Noonan Syndrome: ((ENDO1112)): Features short stature, pulmonary valve stenosis / hypertrophic cardiomyopathy, dysmorphic facies (hypertelorism, downslanting palpebral fissures, ptosis), low-set posteriorly rotated ears, neck webbing, and cryptorchidism. Kallmann syndrome presents with hypogonadotropic hypogonadism and anosmia without these distinct facial/cardiac features.
  • Williams Syndrome: ((ENDO1109)): A contiguous gene deletion syndrome characterized by microdeletion at chromosome 7q11.23 (including the elastin gene). Phenotype includes elfin facies, supravalvular aortic stenosis, peripheral pulmonic stenosis, friendly "cocktail party" personality, and infantile hypercalcemia (in ~10%).

Disorders of Sex Development & Pubertal Abnormalities

  • 5-Alpha Reductase Deficiency: ((ENDO1113)): 46,XY disorder of sex development presenting with ambiguous genitalia, blind-ending vagina/no Müllerian structures, and palpable inguinal/labioscrotal gonads. Characterized by normal FSH, LH, and testosterone with a markedly elevated T:DHT ratio (>17) due to impaired conversion of testosterone to dihydrotestosterone. Partial Androgen Insensitivity Syndrome (PAIS) presents with a normal T:DHT ratio.
  • Hypothalamic Hamartoma: ((ENDO1114)): The most common intracranial lesion causing central precocious puberty (CPP). Appears on MRI as a small pedunculated or sessile mass attached to the tuber cinereum or floor of the third ventricle, producing transforming growth factor-alpha (TGF-$\alpha$) which activates the GnRH pulse generator.
  • McCune-Albright Syndrome: ((ENDO1116)): Triad of peripheral precocious puberty, café-au-lait spots with irregular margins ("Coast of Maine" borders that do not cross the midline), and fibrous dysplasia. Caused by activating missense mutations in the GNAS1 gene (encoding $\text{G}_s$ alpha protein), leading to autonomous ovarian cysts producing estrogen with suppressed FSH and LH.
  • Multiple Pituitary Hormone Deficiency & Midline Defects: ((ENDO1115)): Midline facial anomalies such as a single central incisor serve as a key clinical clue for multiple pituitary hormone deficiency. A complete pituitary profile (evaluating GH, TSH, ACTH, and prolactin axes) is mandatory for workup.

Skeletal Dysplasias & Mineral Metabolism

  • Jansen's Metaphyseal Chondrodysplasia: ((ENDO1108)): Characterized by short-limbed dwarfism with hypercalcemia and radiographic findings of cupped and ragged metaphyses with mottled calcification. Caused by activating mutations of the PTH/PTHrP receptor (PTH1R). Blomstrand chondrodysplasia results from inactivating PTH1R mutations and is lethal.

Nutritional Deficiencies in Thyroid Health

  • Goitrogens & Micronutrient Deficiencies: ((ENDO1117)): Thyroid hormone synthesis and regulation are impacted by key micronutrients: iron deficiency impairs thyroperoxidase activity; selenium deficiency impairs deiodinase and causes peroxide damage; vitamin A deficiency upregulates TSH-$\beta$ transcription via loss of pituitary suppression. Vitamin D deficiency is not a recognized direct contributor to this pathophysiology.